OUR LADY OF FATIMA UNIVERSITY NAME: YANO, YOKO MAE D.

SECTION: 1S GROUP # 3
College of Nursing COURSE: BSN 3Y1-1S DATE: 02/10/2020
SCHEDULE: THURS,FRI,SAT (7-10 AM)

DRUG STUDY Diagnosis: PERICARDITS Patient’s Initials: M.J

DRUG TO DRUG NURSING

MEDICATION ACTION INDICATION CONTRAINDICATION ADVERSE EFFECTS
INTERACTION CONSIDERATION

Generic Name Pharmacodynamics  Documented BCG vaccine live -

Antiarrhythmic action: It is used to treat: hypersentivity; ceftriaxone decreases  Induration after IM  10-g pharmacy bulk
Ceftriaxone Digoxin-induced heart-  Acute bacterial hyperbilirubinemic effects of BCG vaccine live injection package should not be
rate slowing in patients Otitis media neonates, particularly those by pharmacodyamic  Eosinophilia used for direct infusion.
without heart failure is  Intra-abdominal who are premature; antagonism.  Thrombocytosis
negligible and stems infections neonates <28days if they  Diarrhea  Immune-mediated
Brand Name mainly from vagal  Pelvic receive calcium-containing Calcium acetate - do not  Elevated hepatic hemolytic anemia
(cholinergic) and Inflammatory IV products. use ANY calcium transaminases reported; if patient

MCALIM2020
Rocephin sympatholytic effects on
the SA node; however,
Classification with toxic doses, heart-
rate slowing results from
Cephalosporins direct depression of SA
node automaticity.
Inotropic action: The
Dosage & Frequency effect of digoxin on the
myocardium is dose
1g IV q12h related and involves both
direct and indirect
mechanisms
Pharmacokinetics
Stock Dose Absorption: With tablet
or elixir, 60% to 85% of
1 to 2g IV qd dose is absorbed. With
capsule form,
bioavailability increases
Distribution: Distributed
widely in body tissues.
Highest levels occur in the
heart, kidneys, intestine,
stomach, liver, and
skeletal muscle; lowest
levels are in the plasma
and brain. Digoxin crosses
both the blood-brain
barrier and the placental
barrier; fetal and maternal.
Metabolism: In most
patients, a small amount of
digoxin apparently is
metabolized in the liver
and gut by bacteria.
Excretion: Most of dose
is excreted by the kidneys
as unchanged drug.
Disease  Intravenous administration containing solutions in
 Prosthetic joint of ceftriaxone solutions combination with IV
Infection containing lidocaine ceftriaxone; risk of
 Meningitis  Lidocaine contraindications potentially fatal particulate
 Acute if lidocaine solution used as precipitation in lungs,
uncomplicated solvent with ceftriaxone for kidneys. Separate
pyelonephritis intramuscular injection. administration by at least
 Uncomplicated 48hrs.
gonococcal
infections Calcium carbonate - do
 Skin and soft not use ANY calcium
necrotizing containing solutions in
infection combination with IV
 Severe acute ceftriaxone; risk of
bacterial potentially fatal particulate
rhinosinusitis precipitation in lungs,
kidneys. Separate
administration by at least
48hrs.
Calcium Chloride -
contraindicated in neonates
if they require treatment
with calcium containing IV
solutions, including
continous calcium
containing infusions such
as parenteral nutrition
because of the risk of
precipitation of ceftriaxone
and calcium.
Calcium citrate - do not
use ANY calcium
containing solutions in
combination with IV
ceftriaxone; risk of
potentially fatal particulate
precipitation in lungs,
kidneys. Separate
administration by at least
48hrs.
 Leukopenia develops anemia while
 Rash on ceftriaxone, stop
 Increased blood urea antibiotic until etiology
nitrogen (BUN) determined; severe
 Induration at IV site hemolytic anemia,
 Pain including fatalities,
reported in both adults
and children.
 May increase INR,
especially in
nutritionally deficient
patients, hepatic or
renal disease or
prolonged treatment.
 Dosage must be
adjusted in severe renal
insufficiency
 Superinfections and
promotion of
nonsusceptible
organisms may occur
with prolonged use or
repeated therapy.
 Use with caution in
patients with history of
GI disease, especially
colitis.
 Use with caution in
breast-feeding women;
drug may displace
bilirubin from albumin-
binding sites,
increasing risk of
kernicterus.
 Abnormal gallbladder
sonograms reported,
possibly the result of
MCALIM2020
Calcium gluconate - do
not use ANY calcium
containing solutions in
combination with IV
ceftriaxone; risk of
potentially fatal particulate
precipitation in lungs,
kidneys. Separate
administration by at least
48hrs.
Typhoid vaccine live -
ceftriaxone decreases
effects of typhoid vaccine
live by pharmacodynamic
antagonism.
ceftriaxone-calcium
precipitates;
discontinue if signs or
symptoms of
gallbladder disease
occur.
 Use with caution in
patients with history of
GI disease.
MCALIM2020